NASDAQ:BEAM

ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox

Retrieved on: 
Thursday, August 11, 2022

WINSTON-SALEM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (“CKD”), today announced the appointments of John M. Maraganore, Ph.D. and Jennifer Fox to its Board of Directors.

Key Points: 
  • We are thrilled to welcome John and Jen to the ProKidney Board.
  • Previously, Dr. Maraganore served as the founding chief executive officer and as a director of Alnylam Pharmaceuticals, Inc. (Alnylam) (Nasdaq: ALNY), a publicly traded biopharmaceutical company.
  • ProKidney is a company with tremendous potential and I am honored to join its talented Board of Directors, added Dr. Maraganore.
  • With the appointment of Dr. Maraganore and Ms. Fox, ProKidneys Board of Directors has expanded to nine members.

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Beam Therapeutics Inc. with Losses of $100,000 to Contact the Firm

Retrieved on: 
Wednesday, August 3, 2022
Class Action Lawsuit, Professional Services, Legal, Ethics, Food, Suite, Company, Communication, FDA, IND, News, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Certification, NASDAQ, Security (finance), Beam

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Beam Therapeutics Inc. (Beam or the Company) (NASDAQ: BEAM ) for violations of the securities laws.

Key Points: 
  • The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Beam Therapeutics Inc. (Beam or the Company) (NASDAQ: BEAM ) for violations of the securities laws.
  • The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • The Company added that the FDA indicated they will provide an official clinical hold letter to Beam within 30 days.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Beam Therapeutics Inc. with Losses of $100,000 to Contact the Firm

Retrieved on: 
Tuesday, August 2, 2022
Professional Services, Class Action Lawsuit, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Ethics, NASDAQ, News, Certification, FDA, Company, Suite, Communication, IND, Security (finance), Beam

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Beam Therapeutics Inc. (Beam or the Company) (NASDAQ: BEAM ) for violations of the securities laws.

Key Points: 
  • The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Beam Therapeutics Inc. (Beam or the Company) (NASDAQ: BEAM ) for violations of the securities laws.
  • The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • The Company added that the FDA indicated they will provide an official clinical hold letter to Beam within 30 days.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM

Retrieved on: 
Monday, August 1, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, LLP, Company, GLOBE, BEAM, Food, NASDAQ, News, FDA, Communication, Pomerantz, IND, Private investigator, Beam

NEW YORK, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. (Beam or the Company) (NASDAQ:BEAM).

Key Points: 
  • NEW YORK, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. (Beam or the Company) (NASDAQ:BEAM).
  • The investigation concerns whether Beam and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Beam advised investors that [t]he FDA indicated they will provide an official clinical hold letter to Beam within 30 days.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.